This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG670S2_L.jpg
The EU executive agreed to the deal to source Roche’s RoActemra and Merck’s Rebif for supply to any 27 EU members states willing to buy them, the source who is familiar with the issue told Reuters. The person declined to be identified because of the sensitivity of the topic.
The source declined to disclose the terms of the deal.
Roche and Merck were not immediately available for comment. A commission spokeswoman was also not immediately available for comment.
The agreements follow requests from EU states in May to acquire the two drugs which are considered potentially useful against COVID-19.
RoActemra is a drug for rheumatoid arthritis, which has been tested on COVID-19 patients in combination with Gilead (NASDAQ:GILD)’s antiviral remdesivir, the only treatment so far authorised by the European Union for its use against COVID-19.
Rebif is used to treat multiple sclerosis patients. It was originally developed by the Swiss biotech firm Serono before Merck bought the company.
Both drugs target proteins in the body associated with inflammation, and there is some hope that they may help severely ill COVID-19 patients suffering from a so-called cytokine storm, a severe immune system reaction that in some cases has led to organ failure of those infected with the new coronavirus.
The companies said in letters sent to the EU Commission that they could meet demand from EU countries, the EU source said, declining to name the EU states that expressed interest in the drugs.
EU countries have now to agree with the companies on the supplies needed, the source said.
